Table 3. Prognostic evaluation of clinical and histopatological characteristics – Progression Free Survival.

	HR	Lower 95% HR	Upper 95% HR	P-value
Univariate
KRAS-LCS6 (TT vs TG/GG)	0.96	0.65	1.43	0.855
Age at diagnosis	1.01	0.99	10.2	0.267
Treatment arm (docetaxel vs erlotinib)	0.65	0.48	0.89	0.007
Sex (F vs M)	0.76	0.55	1.05	0.100
Smoking (smoking and ex vs not smoking)	1.32	0.92	1.89	0.129
Tumour grade	1.19	0.88	1.60	0.251
Tumour stage (IIIBw/IV vs III vs I/II)	1.16	0.94	1.42	0.172
ECOG-PS (2 vs. 1 vs. 0)	1.79	1.37	2.34	<.0001
Histotype (squamous vs others)	1.22	0.85	1.74	0.278
KRAS (mut vs wt)	1.04	0.73	1.48	0.822
Multivariate
KRAS-LCS6 (TT vs TG/GG)	0.82	0.55	1.22	0.332
Treatment arm (docetaxel vs erlotinib)	0.65	0.48	0.89	0.007
ECOG-PS (2 vs. 1 vs. 0)	1.80	1.37	2.36	<.0001